Search by Title Article Topic - Any -AdvocacyCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA Annual Scientific MeetingHFSA AwardsHFSA Board Certification ReviewHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterHFSA MembershipIn The NewsIndustryJournal of Cardiac FailureMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Mar 30 2022 | Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program Industry News In The News Industry Read More Mar 16 2022 | Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease Industry News In The News Industry Read More Mar 2 2022 | US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction Industry News In The News Industry Read More Feb 28 2022 | Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy Industry News Industry Read More Feb 28 2022 | Cytokinetics announces topline results from METEORIC-HF Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Mar 30 2022 | Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program Industry News In The News Industry Read More
Mar 16 2022 | Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease Industry News In The News Industry Read More
Mar 2 2022 | US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction Industry News In The News Industry Read More
Feb 28 2022 | Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy Industry News Industry Read More
Feb 28 2022 | Cytokinetics announces topline results from METEORIC-HF Industry News Industry Read More
